Parent-Metabolite Pharmacokinetic Modeling and Pharmacodynamics of Veliparib (ABT-888), a PARP Inhibitor, in Patients with BRCA 1/2 - Mutated Cancer or PARP Sensitive Tumor Types

Veliparib (ABT-888) is a novel oral poly-ADP-ribose polymerase (PARP) inhibitor that is being developed for the treatment of hematologic malignancies and solid tumors. Although the pharmacokinetics of veliparib has been studied in combination with cytotoxic agents, limited information exists regardi...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:J Clin Pharmacol
Prif Awduron: Niu, Jing, Scheuerell, Christie, Mehrotra, Shailly, Karan, Sharon, Puhalla, Shannon, Kiesel, Brian F., Ji, Jiuping, Chu, Edward, Gopalakrishnan, Mathangi, Ivaturi, Vijay, Gobburu, Jogarao, Beumer, Jan H.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: 2017
Pynciau:
Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC5503785/
https://ncbi.nlm.nih.gov/pubmed/28387939
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/jcph.892
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg